Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.42 |
| ▸ | HTR1A | P08908 | 1/20 | 0.41 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.41 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.41 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | PIN1 | Q13526 | 2/20 | 0.40 |
| ▸ | BACE1 | P56817 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 4/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.39 |
| ▸ | NPC1 | O15118 | 2/20 | 0.39 |
| ▸ | RAB9A | P51151 | 2/20 | 0.39 |
| ▸ | ATM | Q13315 | 1/20 | 0.39 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18960826 | 0.83 | PTPN1 (0.43) | MAPTHTR1AADRA1DADRA1AADRA1B | |
| SCHEMBL5261603 | 0.81 | KMT2A (0.41) | ALDH1A1HTTMEN1KMT2ANPC1 | |
| SCHEMBL5261599 | 0.81 | KMT2A (0.41) | ALDH1A1HTTMEN1KMT2ANPC1 | |
| SCHEMBL6057897 | 0.78 | TSHR (0.40) | MAPTALDH1A1HTTMEN1KMT2A | |
| SCHEMBL15123629 | 0.78 | MAPT (0.46) | MAPTHTR1AADRA1DADRA1AADRA1B | |
| SCHEMBL11516740 | 0.78 | MEN1 (0.48) | MAPTHTR1AADRA1DADRA1AADRA1B | |
| SCHEMBL10211971 | 0.77 | PTGS2 (0.42) | ALDH1A1HTTKMT2ARAB9APOLB | |
| SCHEMBL15871971 | 0.76 | HTR1A (0.53) | MAPTHTR1AADRA1DADRA1AADRA1B | |
| SCHEMBL428060 | 0.76 | TDP1 (0.40) | MAPTALDH1A1MEN1KMT2ANPC1 | |
| SCHEMBL428061 | 0.76 | TDP1 (0.40) | MAPTALDH1A1MEN1KMT2ANPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1324981-B1 | AMINOPYRIDINYL-, AMINOGUANIDINYL- AND ALKOXYGUANIDINYL- SUBSTITUTED PHENYL ACETAMIDES AS PROTEASE INHIBITORS | ORTHO MCNEIL PHARM INC (US) | 2006-08-23 | — | — | EP | disclosed |
| US-20050159457-A1 | Aminopyridinyl-, aminoguanidinyl- and alkoxyguanidinyl-substituted phenyl acetamides as protease inhibitors | PAN WENXI (US) | 2005-07-21 | — | — | US | disclosed |
| US-6900231-B2 | Aminopyridyl-substituted phenyl acetamides as protease inhibitors | 3-DIMENSIONAL PHARMACEUTICALS, INC. (US) | 2005-05-31 | — | — | US | disclosed |
| EP-1324981-A2 | AMINOPYRIDINYL-, AMINOGUANIDINYL- AND ALKOXYGUANIDINYL- SUBSTITUTED PHENYL ACETAMIDES AS PROTEASE INHIBITORS | 3-DIMENSIONAL PHARMACEUTICALS, INC. (US) | 2003-07-09 | — | — | EP | disclosed |
| US-20030073833-A1 | Aminopyridyl-substituted phenyl acetamides as protease inhibitors | 3-DIMENSIONAL PHARMACEUTICALS, INC. | 2003-04-17 | — | — | US | disclosed |
| US-6521663-B2 | For oral administration or embedded or otherwise attached to medical devices for blood collection and/or treatment | 3-DIMENSIONAL PHARMACEUTICALS, INC. | 2003-02-18 | — | — | US | disclosed |
| US-20020061872-A1 | Aminopyridinyl-, aminoguanidinyl- and Alkoxyguanidinyl-substituted phenyl acetamides as protease inhibitors | 3-DIMENSIONAL PHARMACEUTICALS | 2002-05-23 | — | — | US | disclosed |
| WO-2002028825-A2 | AMINOPYRIDINYL-, AMINOGUANIDINYL- AND ALKOXYGUANIDINYL- SUBSTITUTED PHENYL ACETAMIDES AS PROTEASE INHIBITORS | 3-DIMENSIONAL PHARMACEUTICALS, INC. (US) | 2002-04-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050159457-A1 | Aminopyridinyl-, aminoguanidinyl- and alkoxyguanidinyl-substituted phenyl acetamides as protease inhibitors | F12, TFPI, PLG | MAPT 3068/4885HTR1A 1895/4885ADRA1D 2032/4885 |
| US-20020061872-A1 | Aminopyridinyl-, aminoguanidinyl- and Alkoxyguanidinyl-substituted phenyl acetamides as protease inhibitors | TFPI, PLG, PLAT | MAPT 3360/4885HTR1A 2409/4885ADRA1D 2188/4885 |
| US-20030073833-A1 | Aminopyridyl-substituted phenyl acetamides as protease inhibitors | TFPI, F12, PLAT | MAPT 2792/4885HTR1A 2409/4885ADRA1D 3030/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.